LXEO
Income statement / Annual
Last year (2025), Lexeo Therapeutics Inc.'s total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2025, Lexeo Therapeutics Inc.'s net income was -$99.96 M.
See Lexeo Therapeutics Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2025
|
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
| Period Ended |
12/31/2025 |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
| Operating Revenue |
$0.00 |
$0.00 |
$0.00 |
$654.00 K |
$1.66 M |
$518.48 K |
| Cost of Revenue |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Gross Profit |
$0.00
|
$0.00
|
$0.00
|
$654.00 K
|
$1.66 M
|
$518.48 K
|
| Gross Profit Ratio |
0
|
0
|
0
|
1
|
1
|
1
|
| Research and Development Expenses |
$63.80 M
|
$74.09 M
|
$53.13 M
|
$49.16 M
|
$45.12 M
|
$4.32 M
|
| General & Administrative Expenses |
$45.46 M
|
$31.68 M
|
$15.38 M
|
$12.00 M
|
$7.17 M
|
$787.50 K
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$45.46 M
|
$31.68 M
|
$15.38 M
|
$12.00 M
|
$7.17 M
|
$787.50 K
|
| Other Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Operating Expenses |
$109.26 M
|
$105.77 M
|
$68.51 M
|
$61.16 M
|
$52.29 M
|
$5.11 M
|
| Cost And Expenses |
$109.26 M
|
$105.77 M
|
$68.51 M
|
$61.16 M
|
$52.29 M
|
$5.11 M
|
| Interest Income |
$6.13 M
|
$7.56 M
|
$2.87 M
|
$1.33 M
|
$15.00 K
|
$0.00
|
| Interest Expense |
$206.00 K
|
$114.00 K
|
$205.00 K
|
$91.00 K
|
$0.00
|
$147.15 K
|
| Depreciation & Amortization |
$2.08 M
|
$2.00 M
|
$1.84 M
|
$1.15 M
|
$13.00 K
|
$0.00
|
| EBITDA |
-$97.68 M |
-$96.19 M |
-$64.35 M |
-$58.04 M |
-$50.61 M |
-$4.59 M |
| EBITDA Ratio |
0
|
0
|
0
|
-88.75
|
-30.54
|
-8.85
|
| Operating Income Ratio |
0
|
0
|
0
|
-92.52
|
-30.56
|
-8.85
|
| Total Other Income/Expenses Net |
$9.30 M
|
$7.43 M
|
$2.12 M
|
$1.23 M
|
$15.00 K
|
-$565.00 K
|
| Income Before Tax |
-$99.96 M
|
-$98.33 M
|
-$66.39 M
|
-$59.28 M
|
-$50.62 M
|
-$5.15 M
|
| Income Before Tax Ratio |
0
|
0
|
0
|
-90.64
|
-30.55
|
-9.94
|
| Income Tax Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Net Income |
-$99.96 M
|
-$98.33 M
|
-$66.39 M
|
-$59.28 M
|
-$50.62 M
|
-$5.15 M
|
| Net Income Ratio |
0
|
0
|
0
|
-90.64
|
-30.55
|
-9.94
|
| EPS |
-1.86 |
-3.09 |
-2.49 |
-2.36 |
-2.01 |
-0.2 |
| EPS Diluted |
-1.86 |
-3.09 |
-2.49 |
-2.4 |
-2.01 |
-0.2 |
| Weighted Average Shares Out |
$53.65 M
|
$31.79 M
|
$26.65 M
|
$25.17 M
|
$25.17 M
|
$25.17 M
|
| Weighted Average Shares Out Diluted |
$53.65 M
|
$31.79 M
|
$26.65 M
|
$25.17 M
|
$25.17 M
|
$25.17 M
|
| Link |
|
|
|
|
|
|
